Aon Backs eMed
eMed has raised $200 million at a valuation exceeding $2 billion, positioning itself as a platform focused on employer-sponsored population health, particularly around GLP-1 and GIP therapies. eMed offers clinically supervised weight management programs centered on GLP-1 medications, targeting employers looking to offer these benefits at scale.

